Age Related Macular Degeneration - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Age Related Macular Degeneration - Pipeline Review, H1 2018’, provides an overview of the Age Related Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration

The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects

The report assesses Age Related Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Abzena Plc

Achillion Pharmaceuticals Inc

Aciont Inc

Acucela Inc

AdAlta Ltd

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Alimera Sciences Inc ...

3SBio Inc

Abzena Plc

Achillion Pharmaceuticals Inc

Aciont Inc

Acucela Inc

AdAlta Ltd

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Alimera Sciences Inc

Alkeus Pharmaceuticals Inc

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma

Alteogen Inc

Amarna Therapeutics BV

AngioGenex Inc

Apellis Pharmaceuticals Inc

Apexigen Inc

Applied Genetic Technologies Corp

Astellas Pharma Inc

Benitec Biopharma Ltd

Biokine Therapeutics Ltd

BioMAS Ltd

Biomics Biotechnologies Co Ltd

Biophytis SA

Catalyst Biosciences Inc

Cell Cure Neurosciences Ltd

Cell Medica Ltd

Celon Pharma SA

Charlesson LLC

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Clanotech AB

Coherus BioSciences Inc

Colby Pharmaceutical Co

Crinetics Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

Elasmogen Ltd

Elsalys Biotech SA

Enzene Biosciences Ltd

Exonate Ltd

EyeGate Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

FirstString Research Inc

Foamix Pharmaceuticals Ltd

Formycon AG

Gene Signal International SA

Gene Techno Science Co Ltd

Genentech Inc

GenSight Biologics SA

Graybug Vision Inc

HanAll Biopharma Co Ltd

Huabo Biopharm Co Ltd

Iconic Therapeutics Inc

Ildong Pharmaceutical Co Ltd

Immupharma Plc

Inception Sciences Inc

Innovent Biologics Inc

Ionis Pharmaceuticals Inc

Isarna Therapeutics GmbH

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

Kala Pharmaceuticals Inc

Kodiak Sciences Inc

Lead Discovery Center GmbH

Lee's Pharmaceutical Holdings Ltd

Lin Bioscience Inc

Lupin Ltd

M's Science Corp

Mabion SA

MacuCLEAR Inc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mor Research Application Ltd

Neovacs SA

NGM Biopharmaceuticals Inc

Novartis AG

NovelMed Therapeutics Inc

Ocular Therapeutix Inc

OcuNexus Therapeutics Inc

Ohr Pharmaceutical Inc

OliX Pharmaceuticals Inc

Omeros Corp

Ophthotech Corp

Oxford BioMedica Plc

Oxstem Ltd

PanOptica Inc

Paras Biopharmaceuticals Finland Oy

Pfizer Inc

PlantForm Corp

Profarma

Promedior Inc

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Reliance Life Sciences Pvt Ltd

RheinCell Therapeutics GmbH

Ribomic Inc

RXi Pharmaceuticals Corp

SanBio Inc

SciFluor Life Sciences LLC

Senju Pharmaceutical Co Ltd

Sesen Bio Inc

Stealth BioTherapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

TRACON Pharmaceuticals Inc

Tyrogenex Inc

Unity Biotechnology Inc

Wellstat Ophthalmics Corp

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Age Related Macular Degeneration – Overview 9

Age Related Macular Degeneration – Therapeutics Development 10

Age ...

Table of Contents

Table of Contents 2

Introduction 8

Age Related Macular Degeneration – Overview 9

Age Related Macular Degeneration – Therapeutics Development 10

Age Related Macular Degeneration – Therapeutics Assessment 47

Age Related Macular Degeneration – Companies Involved in Therapeutics Development 59

Age Related Macular Degeneration – Drug Profiles 111

Age Related Macular Degeneration – Dormant Projects 478

Age Related Macular Degeneration – Discontinued Products 496

Age Related Macular Degeneration – Product Development Milestones 499

Appendix 507

List of Tables

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Age Related Macular Degeneration – Pipeline by 3SBio Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Abzena Plc, H1 2018

Age Related Macular Degeneration – Pipeline by Achillion Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Aciont Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Acucela Inc, H1 2018

Age Related Macular Degeneration – Pipeline by AdAlta Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Adverum Biotechnologies Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Aldeyra Therapeutics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Alimera Sciences Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Alkeus Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Allergan Plc, H1 2018

Age Related Macular Degeneration – Pipeline by Allgenesis Biotherapeutics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Allinky Biopharma, H1 2018

Age Related Macular Degeneration – Pipeline by Alteogen Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Amarna Therapeutics BV, H1 2018

Age Related Macular Degeneration – Pipeline by AngioGenex Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Apellis Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Apexigen Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Applied Genetic Technologies Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Astellas Pharma Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Benitec Biopharma Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Biokine Therapeutics Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by BioMAS Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Biomics Biotechnologies Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Biophytis SA, H1 2018

Age Related Macular Degeneration – Pipeline by Catalyst Biosciences Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Cell Cure Neurosciences Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Cell Medica Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Celon Pharma SA, H1 2018

Age Related Macular Degeneration – Pipeline by Charlesson LLC, H1 2018

Age Related Macular Degeneration – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Age Related Macular Degeneration – Pipeline by CJ HealthCare Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Clanotech AB, H1 2018

Age Related Macular Degeneration – Pipeline by Coherus BioSciences Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Colby Pharmaceutical Co, H1 2018

Age Related Macular Degeneration – Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Elasmogen Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Elsalys Biotech SA, H1 2018

Age Related Macular Degeneration – Pipeline by Enzene Biosciences Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Exonate Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by EyeGate Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by EyePoint Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Eyevensys SAS, H1 2018

Age Related Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by FirstString Research Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Foamix Pharmaceuticals Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Formycon AG, H1 2018

Age Related Macular Degeneration – Pipeline by Gene Signal International SA, H1 2018

Age Related Macular Degeneration – Pipeline by Gene Techno Science Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Genentech Inc, H1 2018

Age Related Macular Degeneration – Pipeline by GenSight Biologics SA, H1 2018

Age Related Macular Degeneration – Pipeline by Graybug Vision Inc, H1 2018

Age Related Macular Degeneration – Pipeline by HanAll Biopharma Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Huabo Biopharm Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Iconic Therapeutics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Immupharma Plc, H1 2018

Age Related Macular Degeneration – Pipeline by Inception Sciences Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Innovent Biologics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Isarna Therapeutics GmbH, H1 2018

Age Related Macular Degeneration – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Johnson & Johnson, H1 2018

Age Related Macular Degeneration – Pipeline by Kala Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Kodiak Sciences Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Lead Discovery Center GmbH, H1 2018

Age Related Macular Degeneration – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Lin Bioscience Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Lupin Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by M's Science Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Mabion SA, H1 2018

Age Related Macular Degeneration – Pipeline by MacuCLEAR Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Mitotech SA, H1 2018

Age Related Macular Degeneration – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Mor Research Application Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Neovacs SA, H1 2018

Age Related Macular Degeneration – Pipeline by NGM Biopharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Novartis AG, H1 2018

Age Related Macular Degeneration – Pipeline by NovelMed Therapeutics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Ocular Therapeutix Inc, H1 2018

Age Related Macular Degeneration – Pipeline by OcuNexus Therapeutics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Ohr Pharmaceutical Inc, H1 2018

Age Related Macular Degeneration – Pipeline by OliX Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Omeros Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Ophthotech Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Oxford BioMedica Plc, H1 2018

Age Related Macular Degeneration – Pipeline by Oxstem Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by PanOptica Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018

Age Related Macular Degeneration – Pipeline by Pfizer Inc, H1 2018

Age Related Macular Degeneration – Pipeline by PlantForm Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Profarma, H1 2018

Age Related Macular Degeneration – Pipeline by Promedior Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Ra Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by RegenxBio Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Reliance Life Sciences Pvt Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by RheinCell Therapeutics GmbH, H1 2018

Age Related Macular Degeneration – Pipeline by Ribomic Inc, H1 2018

Age Related Macular Degeneration – Pipeline by RXi Pharmaceuticals Corp, H1 2018

Age Related Macular Degeneration – Pipeline by SanBio Inc, H1 2018

Age Related Macular Degeneration – Pipeline by SciFluor Life Sciences LLC, H1 2018

Age Related Macular Degeneration – Pipeline by Senju Pharmaceutical Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Sesen Bio Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Stealth BioTherapeutics Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Age Related Macular Degeneration – Pipeline by Sylentis SAU, H1 2018

Age Related Macular Degeneration – Pipeline by TRACON Pharmaceuticals Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Tyrogenex Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Unity Biotechnology Inc, H1 2018

Age Related Macular Degeneration – Pipeline by Wellstat Ophthalmics Corp, H1 2018

Age Related Macular Degeneration – Pipeline by Xbrane Biopharma AB, H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..1), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..2), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..3), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..4), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..5), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..6), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..7), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..8), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..9), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..10), H1 2018

Age Related Macular Degeneration – Dormant Projects, H1 2018 (Contd..11), H1 2018

Age Related Macular Degeneration – Discontinued Products, H1 2018

Age Related Macular Degeneration – Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development for Age Related Macular Degeneration, H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Figures

Number of Products under Development for Age Related Macular Degeneration, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports